Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
221 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics. The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects - The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Overview 8 Therapeutics Development 9 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Stage of Development 9 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Therapy Area 10 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Indication 11 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Companies 18 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Products under Development by Universities/Institutes 34 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Therapeutics Assessment 36 Assessment by Monotherapy/Combination Products 36 Assessment by Mechanism of Action 37 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Companies Involved in Therapeutics Development 43 Aduro BioTech, Inc. 43 Agenus, Inc. 44 Aurigene Discovery Technologies Limited 45 BeiGene, Ltd. 46 Beijing Hanmi Pharmaceutical Co., Ltd. 47 BIOCAD 48 Cellular Biomedicine Group, Inc. 49 CytomX Therapeutics, Inc. 50 Eli Lilly and Company 51 Enumeral Biomedical Holdings, Inc. 52 Immunovo BV 53 Jiangsu Hengrui Medicine Co., Ltd. 54 Jounce Therapeutics, Inc. 55 Les Laboratoires Servier SAS 56 MacroGenics, Inc. 57 MD Biosciences GmbH 58 MedImmune, LLC 59 Merck & Co., Inc. 60 Molecular Partners AG 62 Novartis AG 63 Ono Pharmaceutical Co., Ltd. 64 Pfizer Inc. 68 PharmaEssentia Corporation 69 Pieris Pharmaceuticals Inc 70 Regeneron Pharmaceuticals Inc 71 Sutro Biopharma, Inc. 72 Symphogen A/S 73 Tasly Pharmaceutical Group Co., Ltd. 74 Tesaro, Inc. 75 Theravectys SA 76 Tikcro Technologies, Ltd. 77 Vyriad 78 Xencor, Inc. 79 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drug Profiles 80 AM-0001 - Drug Profile 80 AMP-224 - Drug Profile 81 Anti-PD1 Monoclonal Antibody + Cellular Immunotherapy for Glioblastoma - Drug Profile 83 AUR-012 - Drug Profile 84 BGB-108 - Drug Profile 85 BGBA-317 - Drug Profile 86 Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 87 Drug to Inhibit PD-1, Gal-9 and TIM-3 for Solid Tumor - Drug Profile 88 durvalumab + MEDI-0680 - Drug Profile 89 ENUM-003 - Drug Profile 90 ENUM-388D4 - Drug Profile 92 GXP-2 - Drug Profile 93 IBI-308 - Drug Profile 94 JS-001 - Drug Profile 95 MD-402 - Drug Profile 96 mDX-400 - Drug Profile 97 MEDI-0680 - Drug Profile 98 MGD-013 - Drug Profile 99 Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 100 Monoclonal Antibodies to Antagonize PD-1 for Oncology - Drug Profile 101 Monoclonal Antibodies to Antagonize PD1 for Metastatic Melanoma and Metastatic Lung Cancer - Drug Profile 102 Monoclonal Antibodies to Inhibit CTLA4 and PD-1 for Oncology - Drug Profile 103 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 104 Monoclonal Antibody to Antagonize PD-1 for Autoimmune Disorders and Oncology - Drug Profile 105 Monoclonal Antibody to Antagonize PD-1 for Non-Small Cell Lung Cancer - Drug Profile 106 Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 107 Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 108 Monoclonal Antibody to Antagonize PD-1 for Oncology - Drug Profile 109 Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 110 Monoclonal Antibody to Antagonize PD1 for Oncology - Drug Profile 111 Monoclonal Antibody to Inhibit PD-1 and LAG3 for Oncology - Drug Profile 112 Monoclonal Antibody to Inhibit PD-1 and TIM3 for Oncology - Drug Profile 113 Monoclonal Antibody to Inhibit PD-1 for Cancer - Drug Profile 114 Monoclonal Antibody to Inhibit PD-1 for HIV - Drug Profile 115 Monoclonal Antibody to Inhibit PD-1 for Oncology - Drug Profile 116 Monocloncal Antibody to Inhibit PD-1 for Oncology - Drug Profile 117 nivolumab - Drug Profile 118 Oncolytic Virus to Activate IFNb for Head and Neck Cancer and Lewis Lung Cancer - Drug Profile 148 pazopanib hydrochloride + pembrolizumab - Drug Profile 149 PD-1 Antagonist + ropeginterferon alfa-2b - Drug Profile 150 PDR-001 - Drug Profile 151 PEGMP-7 - Drug Profile 152 pembrolizumab - Drug Profile 153 PF-06801591 - Drug Profile 185 PRS-332 - Drug Profile 186 Recombinant Protein to Inhibit VEGF-A and PD1 for Solid Tumor and Hematological Malignancies - Drug Profile 187 REGN-2810 - Drug Profile 188 SHR-1210 - Drug Profile 190 SNPD-07 - Drug Profile 191 STIA-1110 - Drug Profile 192 TSR-042 - Drug Profile 193 Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 194 Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 195 Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 196 XmAb-20717 - Drug Profile 197 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Dormant Projects 198 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Discontinued Products 199 Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Featured News & Press Releases 200 Appendix 216 Methodology 216 Coverage 216 Secondary Research 216 Primary Research 216 Expert Panel Validation 216 Contact Us 216 Disclaimer 217
List of Tables
Number of Products under Development for, H2 2016 13 Number of Products under Development by Therapy Area, H2 2016 14 Number of Products under Development by Indication, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Early Stage Products, H2 2016 20 Comparative Analysis by Unknown Stage Development, H2 2016 21 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Development by Companies, H2 2016 (Contd..3) 27 Products under Development by Companies, H2 2016 (Contd..4) 28 Products under Development by Companies, H2 2016 (Contd..5) 29 Products under Development by Companies, H2 2016 (Contd..6) 30 Products under Development by Companies, H2 2016 (Contd..7) 31 Products under Development by Companies, H2 2016 (Contd..8) 32 Products under Development by Companies, H2 2016 (Contd..9) 33 Products under Development by Companies, H2 2016 (Contd..10) 34 Products under Development by Companies, H2 2016 (Contd..11) 35 Products under Development by Companies, H2 2016 (Contd..12) 36 Products under Development by Companies, H2 2016 (Contd..13) 37 Number of Products under Investigation by Universities/Institutes, H2 2016 38 Products under Investigation by Universities/Institutes, H2 2016 39 Assessment by Monotherapy/Combination Products, H2 2016 40 Number of Products by Stage and Mechanism of Action, H2 2016 42 Number of Products by Stage and Route of Administration, H2 2016 44 Number of Products by Stage and Molecule Type, H2 2016 46 Pipeline by Aduro BioTech, Inc., H2 2016 47 Pipeline by Agenus, Inc., H2 2016 48 Pipeline by Aurigene Discovery Technologies Limited, H2 2016 49 Pipeline by BeiGene, Ltd., H2 2016 50 Pipeline by Beijing Hanmi Pharmaceutical Co., Ltd., H2 2016 51 Pipeline by BIOCAD, H2 2016 52 Pipeline by Cellular Biomedicine Group, Inc., H2 2016 53 Pipeline by CytomX Therapeutics, Inc., H2 2016 54 Pipeline by Eli Lilly and Company, H2 2016 55 Pipeline by Enumeral Biomedical Holdings, Inc., H2 2016 56 Pipeline by Immunovo BV, H2 2016 57 Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 58 Pipeline by Jounce Therapeutics, Inc., H2 2016 59 Pipeline by Les Laboratoires Servier SAS, H2 2016 60 Pipeline by MacroGenics, Inc., H2 2016 61 Pipeline by MD Biosciences GmbH, H2 2016 62 Pipeline by MedImmune, LLC, H2 2016 63 Pipeline by Merck & Co., Inc., H2 2016 64 Pipeline by Molecular Partners AG, H2 2016 66 Pipeline by Novartis AG, H2 2016 67 Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 68 Pipeline by Pfizer Inc., H2 2016 72 Pipeline by PharmaEssentia Corporation, H2 2016 73 Pipeline by Pieris Pharmaceuticals Inc, H2 2016 74 Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 75 Pipeline by Sutro Biopharma, Inc., H2 2016 76 Pipeline by Symphogen A/S, H2 2016 77 Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016 78 Pipeline by Tesaro, Inc., H2 2016 79 Pipeline by Theravectys SA, H2 2016 80 Pipeline by Tikcro Technologies, Ltd., H2 2016 81 Pipeline by Vyriad, H2 2016 82 Pipeline by Xencor, Inc., H2 2016 83 Dormant Projects, H2 2016 202 Discontinued Products, H2 2016 203
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
